195717-63-6

Upstream product

• 3113-72-2 5-methyl-2-nitrobenzoic acid 
• 161292-80-4 methyl 5-((1,3-dioxoisoindolin-2-yl)methyl)-2-nitrobenzoate 
• 159847-81-1 methyl 2-AMINO-5-CYANOBENZOATE 
• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 88071-91-4 5-bromomethyl-2-nitrobenzoic acid methyl ester 
• 20587-30-8 5-methyl-2-nitro-benzoic acid methyl ester 
• 195717-60-3 2-Amino-5-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-benzoic acid methyl ester 

Downstream Products

• 161292-57-5 methyl 2-amino-5-({[(1,1-dimethylethoxy)carbonyl]amino}methyl)benzoate 
• 195717-72-7 {(R)-1-[4-(tert-Butoxycarbonylamino-methyl)-2-(tert-butyl-dimethyl-silanyloxymethyl)-phenylcarbamoyl]-2-naphthalen-2-yl-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 195717-78-3 {3-(tert-Butyl-dimethyl-silanyloxymethyl)-4-[(R)-2-(N',N''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-carbamic acid tert-butyl ester 
• 195717-87-4 5-(tert-Butoxycarbonylamino-methyl)-2-[(R)-2-(N',N''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzoic acid 
• 195717-81-8 {4-[(R)-2-(N',N''-Dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-3-hydroxymethyl-benzyl}-carbamic acid tert-butyl ester 
• 195717-84-1 {4-[(R)-2-(N',N''-Dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-3-formyl-benzyl}-carbamic acid tert-butyl ester 
• 195717-75-0 [4-((R)-2-Amino-3-naphthalen-2-yl-propionylamino)-3-(tert-butyl-dimethyl-silanyloxymethyl)-benzyl]-carbamic acid tert-butyl ester 
• 195717-70-5 [4-Amino-3-(tert-butyl-dimethyl-silanyloxymethyl)-benzyl]-carbamic acid tert-butyl ester 
• 195717-67-0 (4-Amino-3-hydroxymethyl-benzyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Bioorthogonal approach to identify unsuspected drug targets in live cells

A proteomics method to pull down secondary drug targets from live cells is described. The drug of interest is modified with trans-cyclooctene (TCO) and incubated with live cells. Upon cell lysis, the modified drug bound to the protein is pulled down using magnetic beads decorated with a cleavable tetrazine-modified linker. Samples are then run on an SDS-PAGE gel and isolated bands are submitted for mass spectrometry analysis to identify drug targets. Copyright

INHIBITORS OF HCV UPJOHN COMPANY

The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.

Nonpeptide bradykinin antagonist analogs based on a model of a sterling-winthrop nonpeptide bradykinin antagonist overlapped with cyclic hexapeptide bradykinin antagonist peptides

A proposed overlap between cyclic hexapeptide Bradykinin antagonists and nonpeptide Bradykinin antagonists is discussed. Structural variations on both the peptides and nonpeptides support the proposed overlap based on an increase or decrease in the biological activities of the antagonists.